

miRNASelect™ pEGP-miR Cloning and Expression Vector

CATALOG NUMBER: MIR-EXP-GP-C

STORAGE: -80°C

QUANTITY: 100 µL of bacterial glycerol stock

Components

1. miRNASelect™ pEGP-miR Cloning and Expression Vector (Part No. MIR-EXP-GP): One tube
2. miRNASelect™ pEGP-miR Null Control Vector (Part No. MIR-NULL-GP): One tube

Background

MicroRNAs (miRNAs) are 18–24 nucleotide RNA molecules that regulate the stability or translational efficiency of target mRNAs. These regulatory RNAs function by acting as sequence-specific guides which recruit a large protein complex known as the RNA-induced silencing complex (RISC) to target mRNAs which are subsequently silenced. Diverse functions have been attributed to miRNAs including the regulation of cellular differentiation, proliferation, and apoptosis. Moreover, significant evidence has accumulated implicating a fundamental role for miRNAs in the development of cancer.

miRNAs are initially transcribed as long precursor transcripts known as primary microRNAs (pri-miRNAs). Within these transcripts, the mature miRNA sequences are found in ~60–80 nucleotide hairpin structures. Mature miRNAs are generated from pri-miRNAs by sequential processing (Figure 1). Pri-miRNAs are initially recognized in the nucleus by the microprocessor complex which includes as core components the RNase-III enzyme Drosha and its obligate partner DGCR8. This complex excises the hairpin structure containing the mature miRNA sequence. The liberated hairpins, referred to as precursor miRNAs (pre-miRNAs), are recognized by the nuclear export factor exportin 5 which transports them to the cytoplasm. There, the RNase-III enzyme Dicer performs a second cleavage to generate a double-stranded 18–24 nucleotide RNA molecule. The RISC then associates with this RNA duplex and unwinds it. Generally, only one strand is stably incorporated into the RISC; the other is discarded and rapidly degraded. miRNAs guide the RISC to target messages that are subsequently cleaved or translationally silenced.

Synthetic miRNA molecules based on predicted mature miRNA sequence are sometimes used. Despite their optimized design criteria, synthetic miRNAs underscore the importance of primary miRNA in its native expressed form. The primary miRNA contains critical biological components involved in mature miRNA expression and cellular processing, and is often processed into several mature miRNA molecules.

Cell Biolabs' miRNASelect™ Cloning and Expression Vector is designed to clone and express an individual miRNA precursor in its native context while preserving putative hairpin structures to ensure biologically relevant interactions with endogenous processing machinery and regulatory partners, leading to properly cleaved microRNAs. Individual miRNA precursor from any species can be cloned between BamHI and Nhe I sites (Figure 2).




Figure 1. miRNA Biogenesis and function

The miRNASelect™ pEGP-miR cloning and expression vector contains the following features:

- **miRNA Processing** – miRNA stem loop precursor in its native context is cloned between BamHI and Nhe I sites. To preserve the putative hairpin structure and proper endogenous processing, miRNA stem loop sequence is flanked by its native intron sequence.
- **EF-1 α Promoter** - ensures a high level of expression in mammalian cells
- **GFP-Puro Fusion Marker** - to monitor cells positive for expression and stable selection with either GFP or puromycin resistance.
- **SV40 Polyadenylation Signal** - enables efficient termination of transcription
- **pUC Origin** - for high copy replication and maintenance of the plasmid in *E. coli*
- **Ampicillin Resistance Gene** - for selection in *E. coli*




Figure 2. Schematic representation of pEGP-miR cloning and expression vector.

miRNA precursor cloning sites: BamHI - mmu- 304 bp - NheI

```
CGATTAGTTCTCGAGGATCCGACTGTTCTTTTCCCTCATTACACAGGAAACCGGAATTACAAAG
GAGAACGGCTTCCTGTGATGCTCAGCTGTGATTACTTTCAACATTCACCCTGGATGTTCTCTTC
ACTGTGGGATGAGGTAGTAGGTTGTATAGTTTTAGGGTCACACCCACCACTGGGAGATAACTAT
ACAATCTACTGTCTTTCTAAGGTGATGGAAAAGTCTGCATTCATGGGGTCTCATAGGAAACCA
AGAACAAACTGCAGTGTTTTAAAGTATATCTTGCCTTAAAAGCATTTGCTTATGCTATGCATGA
AGTCGCTAGCTCGAGCTTTTGGAG
```

Note: pEGP-miR Cloning and Expression Vector should NOT be used as a transfection control vector, because the vector itself contains 304 bp of mmu-let7a-1 precursor sequence between the BamHI and NheI sites. For transfection control, we recommend pEGP-miR Null Control Vector.

Cell Biolabs' miRNASelect™ pEGP-miR Null Control Vector is similar to the pEGP-miR Cloning and Expression Vector except it does not contain any miRNA precursor (Figure 3).




Figure 3. Schematic representation of the miRNASelect™ pEGP-miR Null control vector.

Note: pEGP-miR Null Control Vector should NOT be used as a cloning vector, because the vector will not be digested well with BamHI due to secondary structure.

miRNA Precursor Cloning

All of our premade human and mouse miRNA precursor clones are based on the following design, and the resulting overexpression of the mature miRNA is confirmed by Northern blot. Here we use human let-7a-2 miRNA as an example:

1. Download desired miRNA stem loop sequence from Sanger's miRNA database:

<http://microrna.sanger.ac.uk/sequences/>

Homo sapiens let-7a-2 stem-loop structure

uu g u

agg gag uag agguuguauauguu u c u
||| ||| ||| ||| ||| ||| ||| | | c
ucc uuc auc uccgacaugucaaa a g a
- u g c - --uag gg a

Homo sapiens let-7a-2 stem-loop sequence

AGGUUGAGGUAGUAGGUUGUAUAGUUAGAAUACAUCAAGGGAGAUAAACUGUACAGCCUCCUAGCUUUCU

2. Blast search miRNA stem loop sequence: <http://blast.ncbi.nlm.nih.gov/Blast.cgi>

```
> ref|NT\_033899.7|Hs11\_34054  Homo sapiens chromosome 11 genomic contig,  
reference assembly  
Length=38509590
```

Query	1	AGGTTGAGGTAGTAGGTTGTATAGTTTAGAATTACATCAAGGGAGATAACTGTACAGCCT	60
Sbjct	25579717	AGGTTGAGGTAGTAGGTTGTATAGTTTAGAATTACATCAAGGGAGATAACTGTACAGCCT	
	25579658		
Query	61	CCTAGCTTTCCT	72
Sbjct	25579657	CCTAGCTTTCCT	25579646

3. PCR and Cloning:

- 1) Add 100 base native flank sequence to both upstream and downstream of the miRNA stem loop.

Human let-7a-2 miRNA precursor sequence including the 100 base flank sequences on both ends of the stem loop: let-7a-2 stem-loop sequence is underlined.

GCCCAAATAGGTGACAGCACGATGAATCATTATAAGACTAACTTGTAAATTTCCCTGCTTAAGAAATG
 GTAGTTTTCCAGCCATTGTGACTGCATGCTCCCAGGTTGAGGTAGTAGGTTGTATAGTTTAGAATTA
CATCAAGGGGAGATAACTGTACAGCCTCCTAGCTTTCCCTTGGGTCTTGCACTAAACAACATGGTGAGA
 ACGATCATGATTCCTCCAGGCCTTTTCTCCCTATGAAAGGTAAGATTGGGTACGATTATTTTATGGT
 AATT

- 2) Design PCR primer including BamHI site at forward primer with four extra bases and NheI site at reverse primer.

Forward PCR Primer: tcga-ggatcc (BamHI)-21 nt
Reverse PCR Primer: tcga-gctagc (NheI)-21 nt

For human let-7a-2 miRNA precursor:

Forward PCR Primer: tcga-ggatcc-gcccaaataggtgacagcacg
Reverse PCR Primer: tcga-gctagc-aaataccataaaataatcgta

- 3) PCR the miRNA precursor from genomic DNA and clone into the BamHI/NheI sites of the expression vector.

PCR Product of let-7a-2 precursor: let-7a-2 stem-loop sequence is underlined.

```
1  tcgaggatcc  gcccaaata  gtgacagcac  gatgaatcat  tataagacta  acttgtaatt
61  tccctgctta  agaaatggta  gttttccagc  cattgtgact  gcatgctccc  aggttgaggt
121 agtaggttgt  atagttttaga  attacatcaa  gggagataac  tgtacagcct  cctagctttc
181 cttgggtctt  gcactaaaca  acatggtgag  aacgatcatg  attcctccag  gccttttctc
241 cctatgaaag  gtaagattgg  gtacgattat  tttatggtat  ttgctagctc  ga
```

4) Validate the insert by DNA sequencing.

Forward Sequencing Primer: TTTGCACCATTCTAAAGAAT

Reverse Sequencing Primer: AAACCTCTTACATCAGTTAC

Methods

- 1) Bacterial culture: the miRNA cloning and expression vector is provided as bacterial glycerol stock. Individual colonies can be obtained by culturing in an LB-ampicillin plate.
- 2) Plasmid isolation: we recommend EndoFree Plasmid Kits (QIAGEN).
- 3) Transfection into target cells: we recommend Lipofectamine 2000 (Invitrogen).
- 4) Stable selection: 48 hrs post-transfection, select stable clones by green fluorescence sorting or Puromycin resistance in 1-10 µg/mL Puromycin-containing medium.

References

1. microRNA sequences listed in Sanger's miRBase (<http://microrna.sanger.ac.uk/sequences/>).
2. John, B., C. Sander and D. S. Marks (2006) *Methods Mol Biol* **342**: 101-13.
3. Johnson, S. M., H. Grosshans, J. Shingara, M. Byrom, R. Jarvis, A. Cheng, E. Labourier, K. L. Reinert, D. Brown and F. J. Slack (2005) *Cell* **120**: 635-47.
4. Kim, V. N. (2005) *Mol Cells* **19**: 1-15.
5. Lee, R. C., R. L. Feinbaum and V. Ambros (1993) *Cell* **75**: 843-54.
6. Lee, Y., K. Jeon, J. T. Lee, S. Kim and V. N. Kim (2002) *Embo J* **21**: 4663-70.
7. Yi, R., Y. Qin, I. G. Macara and B. R. Cullen (2003) *Genes Dev* **17**: 3011-6..

Appendix

Vector Features:

130 ~ 525: EF-1 α Promoter
558 ~ 1342: human β -globin intron
774 ~ 779: BamHI
1084 ~ 1089: NheI
1370 ~ 2692: GFP-Puro Fusion (GFP: 1370 ~ 2086; Puro: 2093 ~ 2692)
2712 ~ 2842: SV40 PolyA
3051 ~ 3911: Ampicillin Resistance

Plasmid Sequence:

CCCAACTTTTTAAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAAGAATAGTAGACATAATAGCAACAGACATACAAACT
AAAGAATTACAAAAACAAATTACAAAATTTCAAAATTTTATCGATGCTTCCCGTCAACCACCCCCCAACCCGCCCGACCGGAG
CTGAGAGTAATTCATACAAAAGGACTCGCCCTGCTTGGGGAATCCAGGGACCGTCGTTAAACTCCCACTAACGTAGAACCCA
GAGATCGCTGCGTTCCCGCCCCCTCACCCGCCCGCTCTCGTCATCACTGAGGTGGAGAAGAGCATGCGTGAGGCTCCGGTGCCCCG
TCAGTGGGCGAGAGCGACATCGCCACAGTCCCCGAGAAGTTGGGGGAGGGGTGCGCAATTGAACCGGTGCTTAGAGAAGGTGG
CGCGGGGTAAACTGGGAAAGTGATGTCGTGACTGGCTCCGCTTTTCCCGAGGGTGGGGGAGAACCGTATATAAAGTGCAGTAG
TCGCGGTGAACGTTCTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTACACATATTGACCAAAATCAGGGTAATTTTGCATTTG
TAATTTTAAAAAATGCTTCTCTTTAATACTTTTTGTTTATCTTATTCTAATACTTTCCCTAATCTCTTCTTTTCAGGG
CAATAATGATACAATGTATCATGCCTCTTTCACCACTTCTAAAGAATAACAGTGATAATTTCTGGGTAAAGGCAATAGCCGATTA
GTTCTCGAGGATCCGACTGTTCTTTTCCCTCATTACACAGGAAACCGGAATTACAAAGGAGAACGGCTTCTGTGATGCTCAGCT
GTGATTACTTTCAACATTACCCCTGGATGTTCTCTTCACTGTGGGATGAGGTAGTAGGTTGTATAGTTTATAGGGTCACACCCACC
ACTGGGAGATAAATACTATAAATCTACTGTCTTTCTAAGGTGATGGAAAAGTCTGCATTTCATGGGGTCTCATAGGAAACCAAGAAC
AAACTGCAGTGTTTTAAAGTATATCTTGCTTAAAGCATTTGCTTATGCTATGCATGAAGTCGCTAGCTCGAGCTTTTGAGAA
TATTTCTGCATATAAATATTTCTGCATATAAATGTAAGTGTGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCCAGCTA
CCATTCTGCTTTTATTTTATGGTTGGGATAAGGCTGGATTATTCTGAGTCCAAGCTAGGCCCTTTTGTAAATCATGTTTCATACCT
CTTATCTTCTCCACAGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAGCACGTGAGATCTGAATTC
TGACACACCATGGTGAGCAAGGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCTGGTCGAGCTGGACGGCGACGTAAACGGCC
ACAAGTTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCTGAAGTTTCATCTGCACCAACCGGCAAGCT
GCCCGTGCCCTGGCCACCCCTCGTGACCACCCCTGACCTACGGCGTGAGTGCTTCAGCCGCTACCCCGACCATGAAGCAGCAC
GACTTCTTCAAGTCCGCCATGCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCG
CCGAGGTGAAGTTTCGAGGGCGACACCCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGG
GCACAAGCTGGAGTACAATAACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAGCGCATCAAGGTGAACCTTCAAG
ATCCGCCACAACATCGAGGACGGCAGCGTGAGCTCGCCGACCACTACCAAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGC
TGCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAGAGCCCAACGAGAGAAGCGCATCATGTTCTGCTGGAGTT
CGTGACCGCCCGCGGATCACTCTCGGCATGGACGAGCTGTACAAGGCCACCATGACCGAGTACAAGCCACGGTGCGCTCGCC
ACCCGCGACGACGTCCCAAGGGCGTACGACCCCTCGCGCGCGTTCGCGACTACCCGCGACGCGCCACACCGTCGATCCGG
ACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAATCTTCTCACGCGCGTTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGA
CGACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTGAAGCGGGGGCGGTGTTTCGCCGAGATCGGCCCGCGCATGGCC
GAGTTGAGCGGTTCCCGGCTGGCGCGCAGCAACAGATGGAAGGCTCTGGCGCGCACCGGCCAAGGAGCCCGGTGGTTCC
TGCCACCGCTCGCGGTCTCGCCCGACCAACAGGGCAAGGGTCTGGGCAAGCGCGTCTGCTCTCCCGGAGTGAGGGCGGGCGAGCG
CGCCGGGGTGCCCGCTTCTGGAGACCTCCGCGCCCCGCAACCTCCCTTCTACGAGCGGCTCGGCTTACCGTCAACCGCGAC
GTCGAGTGCCGAAGGACCGCGACCTGGTGATGACCGCAAGCCCGGTGCTGACGCGCGCAATCTAGACCAAACTTGT
ATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTCTACTGCATTCTAGTTGTG
GTTTGTCCAACTCATCAATGTATCTTATCATGTCTGTGATCAGGTACCAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAA
TGTCATGATAATAATGGTTTCTTAGACGTGAGGTGGCACTTTTCGGGGAATGTGCGCGGAACCCCTATTTGTTTATTTTCTAA
ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCGTGATAAATGCTTCAATAATTGAAAAAGGAAGAGTATGAGTATTC
AACATTTCCGTGTGCGCTTATTTCCCTTTTTTTCGCGCATTTTGCCTTCTGTTTTTCTCACCCAGAAACGCTGGTGAAAGTAAA
AGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCC
GAAGAACGTTTTTCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGTATTATCCGTATTGACGCCGGGAAGAGCAAC
TCGGTGCGCCGATACACTATTCTCAGAATGACTTGGTTGAGTACTACCAAGTACAGAAAAGCATCTTACGGATGGCATGACAGT
AAGAGAATTATGAGTGCTGCCATAACCATGAGTGATAAAGTGCAGGCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAG
CTAACCGCTTTTTTGCACAACATGGGGATCATGTAACCTGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAACG
ACGAGCGTGACACACGATGCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAGTGGCGAATCTTACTCTAGCTTCCCG
GCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCT
GATAAATCTGGAGCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTA
TCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAAGCATTGGTA
ACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAACTTCAATTTTTAATTAAGGATCTAGGTGAAGATCCTTT
TTGATAATCTCATGACCAAAATCCCTAACGTGAGTTTTGTTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAGGATCTTC
TTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAAACAAAAAACACCGCTACCAAGCGGTGGTTTTGTTTGGCGGATCAA
GAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAATACTGTTCTTCTAGTGTAGCCGTAGTTAG
GCCACCACTTCAAGAACTCTGTAGACCGCCTACATACTCGCTCTGCTAATCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAA
GTCGTGCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGGTGAACGGGGGGTTCGTGCACACAG
CCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAAGCGCCACGCTTCCCGAAGGGAGAA
AGGCGGACAGGTATCCGGTAAGCGGACGGGTGGGAACAGGAGCGCAGAGGGAGCTTCCAGGGGGAAACGCTTGGTATCTTTA
TAGTCTGTGCGGGTTTCGCCACCTCTGACTTGAGCGTCAATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCC
AGCAACGCGGCTTTTTACGGTTTCTGGCTTTTGTGCTGCTTTTGTGCTCAGATGTTCTTTCTGCGTTATCCCTGATTCTGTGG
ATAACCGTATTACCGCTTTGAGTGAGCTGATACCGCTCGCCGACCGCAACGACCGAGCGCAGCGAGTCACTGAGCGAGGAAGC
GGAAGAGCGCCCAATACGCAACCGCCTCTCCCCGCGCGTTGGCCGATTATTAATGCAGCTGGCACGACAGGTTTCCCGACTGG
AAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTC

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY

AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

This product is for RESEARCH USE ONLY; not for use in diagnostic procedures.

Contact Information

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2009: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.